Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RXRX
stocks logo

RXRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
25.68M
+464.97%
-0.346
-34.72%
16.28M
+10.41%
-0.363
-27.33%
17.94M
-6.67%
-0.347
-15.45%
Estimates Revision
The market is revising Downward the revenue expectations for Recursion Pharmaceuticals, Inc. (RXRX) for FY2025, with the revenue forecasts being adjusted by -9.73% over the past three months. During the same period, the stock price has changed by 6.72%.
Revenue Estimates for FY2025
Revise Downward
down Image
-9.73%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.38%
In Past 3 Month
Stock Price
Go Up
up Image
+6.72%
In Past 3 Month
Wall Street analysts forecast RXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXRX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast RXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXRX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.920
sliders
Low
8.00
Averages
8.00
High
8.00
Current: 4.920
sliders
Low
8.00
Averages
8.00
High
8.00
Morgan Stanley
Equal Weight
initiated
$5
2025-07-03
Reason
Morgan Stanley
Price Target
$5
2025-07-03
initiated
Equal Weight
Reason
Morgan Stanley assumed coverage of Recursion Pharmaceuticals with an Equal Weight rating and $5 price target. Recursion has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. The recent pipeline prioritization and stage of clinical development for the proprietary pipeline leaves several open questions on valuation, the analyst tells investors in a research note.
Morgan Stanley
Equal Weight
downgrade
$8 -> $5
2025-06-17
Reason
Morgan Stanley
Price Target
$8 -> $5
2025-06-17
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on Recursion Pharmaceuticals to $5 from $8 and keeps an Equal Weight rating on the shares. The firm revised its model following the company's recent pipeline prioritizations, cost reductions, 20% workforce reduction and updated cash burn guidance.
Morgan Stanley
Vikram Purohit
Hold
Maintains
$10 → $8
2025-04-10
Reason
Morgan Stanley
Vikram Purohit
Price Target
$10 → $8
2025-04-10
Maintains
Hold
Reason
Morgan Stanley lowered the firm's price target on Recursion Pharmaceuticals to $8 from $10 and keeps an Equal Weight rating on the shares. The firm updated its model based on commentary through Q4 earnings and following the recent opportunity it had to catch-up with management on the current status of the pipeline, the analyst tells investors.
Needham
Gil Blum
Strong Buy
Reiterates
$11
2025-04-08
Reason
Needham
Gil Blum
Price Target
$11
2025-04-08
Reiterates
Strong Buy
Reason
Leerink Partners
Mani Foroohar
Hold
Maintains
$7 → $6
2025-02-28
Reason
Leerink Partners
Mani Foroohar
Price Target
$7 → $6
2025-02-28
Maintains
Hold
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$11
2025-02-06
Reason
Needham
Gil Blum
Price Target
$11
2025-02-06
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Recursion Pharmaceuticals Inc (RXRX.O) is -3.51, compared to its 5-year average forward P/E of -7.45. For a more detailed relative valuation and DCF analysis to assess Recursion Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.45
Current PE
-3.51
Overvalued PE
-1.25
Undervalued PE
-13.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.43
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.86
Undervalued EV/EBITDA
-13.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
85.00
Current PS
0.00
Overvalued PS
222.54
Undervalued PS
-52.54
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 156.51% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 156.51% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

RXRX News & Events

Events Timeline

(ET)
2025-12-02
20:10:00
ARK Investment Acquires 338K Shares of Recursion Pharmaceuticals Today
select
2025-11-05 (ET)
2025-11-05
06:38:23
Najat Khan named CEO of Recursion, starting January 1
select
2025-11-05
06:35:36
Recursion Pharmaceuticals announces Q3 EPS of 36 cents, below consensus estimate of 38 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
07:55 AMCNBC
Cramer's Lightning Round: Recursion Pharmaceuticals 'has performed poorly'

  • Market Commentary: Recursion Pharmaceuticals' stock performance has been disappointing, leading to skepticism about recommending it.

  • Investment Resources: Jim Cramer offers a free guide to investing aimed at helping individuals build long-term wealth and improve their investment strategies.

[object Object]
Preview
3.0
11-24NASDAQ.COM
Is Recursion Pharmaceuticals Poised to Become a Leading AI Stock?

  • Recursion Pharmaceuticals' Potential: Recursion Pharmaceuticals aims to revolutionize drug development using AI and machine learning, with a focus on reducing the time and costs associated with bringing new drugs to market.

  • Pipeline and Partnerships: The company has several promising candidates in its pipeline, including a potential cancer treatment, and has formed partnerships with major pharmaceutical companies like Bayer and Merck, which lend credibility to its strategy.

  • Risks and Challenges: Despite its innovative approach, Recursion faces significant risks, including the lack of market-ready products, competition from larger drugmakers, and the inherent uncertainties of clinical trials.

  • Investment Considerations: Analysts caution that Recursion Pharmaceuticals is not currently recommended as a top investment, with other stocks identified as better opportunities for potential returns.

[object Object]
Preview
5.0
11-21TipRanks
Cathie Wood Acquires Nvidia, ACHR, and Cryptocurrency Stocks While Selling AMD and EXAS

  • ARK Invest's Notable Purchases: Cathie Wood's ARK Invest made significant portfolio adjustments, including buying 93,374 shares of Nvidia and 971,423 shares of Archer Aviation, alongside various crypto stocks and biotech companies.

  • Position Trimming: ARK continued to reduce its stake in Advanced Micro Devices (AMD) by selling 14,087 shares and offloaded 932,161 shares of Exact Sciences following its acquisition by Abbott Laboratories.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Recursion Pharmaceuticals Inc (RXRX) stock price today?

The current price of RXRX is 4.92 USD — it has increased 5.58 % in the last trading day.

arrow icon

What is Recursion Pharmaceuticals Inc (RXRX)'s business?

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

arrow icon

What is the price predicton of RXRX Stock?

Wall Street analysts forecast RXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXRX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Recursion Pharmaceuticals Inc (RXRX)'s revenue for the last quarter?

Recursion Pharmaceuticals Inc revenue for the last quarter amounts to 5.18M USD, decreased -80.16 % YoY.

arrow icon

What is Recursion Pharmaceuticals Inc (RXRX)'s earnings per share (EPS) for the last quarter?

Recursion Pharmaceuticals Inc. EPS for the last quarter amounts to -0.36 USD, increased 5.88 % YoY.

arrow icon

What changes have occurred in the market's expectations for Recursion Pharmaceuticals Inc (RXRX)'s fundamentals?

The market is revising Downward the revenue expectations for Recursion Pharmaceuticals, Inc. (RXRX) for FY2025, with the revenue forecasts being adjusted by -9.73% over the past three months. During the same period, the stock price has changed by 6.72%.
arrow icon

How many employees does Recursion Pharmaceuticals Inc (RXRX). have?

Recursion Pharmaceuticals Inc (RXRX) has 840 emplpoyees as of December 05 2025.

arrow icon

What is Recursion Pharmaceuticals Inc (RXRX) market cap?

Today RXRX has the market capitalization of 2.56B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free